Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2004
  • Online publication date: December 2009

9 - Instruments to measure the specific health impact of surgery, radiation, and chemotherapy on cancer patients

Summary

Introduction

Surgery, radiation, and chemotherapy are used to cure, to prolong life, and to palliate symptoms of cancer patients. These treatments can have complicated effects on the patients who receive them. Their therapeutic effects on the cancers are intended to preserve or improve health status over time. However, these therapies can cause short-term and long-term adverse effects that result in deterioration in health status.– Prescribing these treatments requires a careful assessment of the risks and benefits of the proposed therapy by both the treating physician and patient. In situations where the benefits are curing the disease and the risks are minimal, treatment decisions are straightforward. Conversely, in situations where benefits are marginal, such as modest improvements in survival or palliation of symptoms, and the risks include treatment-related morbidity, treatment decisions are more difficult. If the fundamental question to be addressed by health care professionals and patients before prescribing treatment is “Does the toxicity and/or the inconvenience of the proposed treatment justify the expected gain?” then providing data on the impact of therapy on patient health from carefully conducted clinical studies, using robust instruments designed to assess impact of treatment-related morbidities specifically, could provide useful information. The purpose of this chapter is to review the treatment-specific instruments that have been developed and discuss their potential role in assessing the impact of therapy on cancer patients.

REFERENCES
Donovan, K., Sanson-Fisher, R., Redman, S. (1989). Measuring quality of life in cancer patients.Journal of Clinical Oncology 7:959–68
Scott, C. B. (1998). Issues in quality of life assessment during cancer therapy. Seminars in Radiation Oncology 8:5–9
Carlsson, M., Strang, P., Bjurstrom, C. (2000). Treatment modality affects long-term quality of life in gynaecological cancer.Anticancer Research 20(1B):563–8
Langenhoff, B. S., Krabbe, P. F., Wobbes, T.et al. (2001). Quality of life as an outcome measure in surgical oncology.British Journal of Surgery 88:643–52
Cox, J., Stetz, J., Pajak, T. (1995). Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).International Journal of Radiation Oncology, Biology, and Physics 31:1341–6
Paszat, L., Mackillop, W., Groome, P.et al. (1998). Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries.Journal of Clinical Epidemiology 16:2625–31
National Cancer Institute (2001). CancerNet PDQ Cancer Information Summary. Breast Cancer Treatment (for health professionals). http://www.cancer.gov/cancerinfo/pdq/treatment/breast/healthprofessional. Last accessed September 11, 2004
National Cancer Institute (2001). CancerNet PDQ Cancer Information Summary. Colon Cancer Treatment (for health professionals). http://www.cancer.gov/cancerinfo/pdq/treatment/colon/healthprofessional. Last accessed September 11, 2004
National Cancer Institute (2001). CancerNet PDQ Cancer Information Summary. Rectal Cancer Treatment (for health professionals). http://www.cancer.gov/cancerinfo/pdq/treatment/rectal/healthprofessional. Last accessed September 11, 2004
National Cancer Institute (2001). CancerNet PDQ Cancer Information Summary. Non-small Cell Lung Cancer Treatment (for health professionals). http://www.cancer.gov/cancerinfo/pdq/treatment/non-small-cell-lung/healthprofessional. Last accessed September 11, 2004
National Cancer Institute (2002). CancerNet PDQ Cancer Information Summary. Small Cell Lung Cancer Treatment (for health professionals). http://www.cancer.gov/cancerinfo/pdq/treatment/small-cell-lung/healthprofessional. Last accessed September 11, 2004
National Cancer Institute (2001). CancerNet PDQ Cancer Information Summary. Prostate Cancer Treatment (for health professionals). http://www.cancer.gov/cancerinfo/pdq/treatment/prostate/healthprofessional. Last accessed September 11, 2004
Smets, E. M., Garssen, B., Bonke, B.et al. (1995). The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue.Journal of Psychosomatic Research 39:315–25
Smets, E. M., Garssen, B., Cull, A.et al. (1996). Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy.British Journal of Cancer 73:241–5
Smets, E. M., Visser, M. R., Garssen, B.et al. (1998). Understanding the level of fatigue in cancer patients undergoing radiotherapy.Journal of Psychosomatic Research 45:277–93
Ahsberg, E., Furst, C. J. (2001). Dimensions of fatigue during radiotherapy — an application of the Swedish Occupational Fatigue Inventory (SOFI) on cancer patients.Acta Oncologia 40:37–43
Hopwood, P. (1993). The assessment of body image in cancer patients.European Journal of Cancer 29A:276–81
Klee, M. C., King, M. T., Machin, D.et al. (2000). A clinical model for quality of life assessment in cancer patients receiving chemotherapy.Annals of Oncology 11(1):23–30
Broecke, J. A., Jacobsen, P. B., Balducci, L.et al. (2000). Quality of life after adjuvant chemotherapy for breast cancer.Breast Cancer Research and Treatment 62(2):141–50
Dam, F. S., Schagen, S. B., Muller, M. J.et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.Journal of the National Cancer Institute 90:210–18
Schagen, S. B., Dam, F. S., Muller, M. J.et al. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.Cancer 85:640–50
Brezden, C. B., Phillips, K. A., Abdolell, M.(2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy.Journal of Clinical Oncology 18:2695–701
Hurny, C., Bernhard, J., Coates, A. (1998). Quality of life assessment in the International Breast Cancer Study Group: past, present, and future.Recent Results in Cancer Research 152:390–5
Hurny, C., Bernhard, J., Coates, A. S.et al. (1996). Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group.Lancet 347:1279–84
Fairclough, D. L., Fetting, J. H., Cella, D.et al. (1999). Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG).Quality of Life Research 8:723–31
Douillard, J. Y., Cunningham, D., Roth, A. D.et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.Lancet 355(9209):1041–7
Cunningham, D., Pyrhonen, S., James, R. D.et al. (1998). Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.Lancet 352(9138):1413–18
Rougier, P., Cutsem, E., Bajetta, E.et al. (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.Lancet 352(9138):1407–12
Osoba, D., Tannock, I. F., Ernst, D. S.et al. (1999). Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.Journal of Clinical Oncology 17:1654–63
Cullen, M. H., Billingham, L. J., Woodroffe, C. M.et al. (1999). Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.Journal of Clinical Oncology 17:3188–94
Shepherd, F. A., Dancey, J., Ramlau, R.et al. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.Journal of Clinical Oncology 18:2095–103
Hakamies-Blomqvist, L., Luoma, M., Sjostrom, J.et al. (2000). Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.European Journal of Cancer 36:1411–17
Kramer, J. A., Curran, D., Piccart, M.et al. (2000). Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.European Journal of Cancer 36:1488–97
Harper-Wynne, C., English, J., Meyer, L.et al. (1999). Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.British Journal of Cancer 81:316–22
Cella, D., Tulsky, D., Gray, G.et al. (1993). The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure.Journal of Clinical Oncology 11:570–9
Brundage, M., Pater, J., Zee, B. (1993). Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.Journal of the National Cancer Institute 85:1138–48
Pavy, J. J., Denekamp, J., Letschert, J.et al. (1995). Late effects toxicity scoring: the SOMA Scale.International Journal of Radiation Oncology, Biology, and Physics 31:1043–7
Rubin, P., Constine, L., Fajardo, L.et al. (1995). Overview: Late effects of normal tissues (LENT) scoring system.International Journal of Radiation Oncology, Biology, and Physics 31:1041–2
Trotti, A., Byhardt, R., Stetz, J.et al. (2000). Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy.International Journal of Radiation Oncology, Biology, and Physics 47:13–47
Franklin, H., Simonetti, G., Dubbelman, A.et al. (1994). Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting.Annals of Oncology 5:113–17
Anacak, Y., Yalman, D., Ozsaran, Z.et al. (2001). Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems.International Journal of Radiation Oncology, Biology, and Physics 50:1107–12
Bruner, D., Wasserman, T. (1995). The impact on quality of life by radiation late effects.International Journal of Radiation Oncology, Biology, and Physics 31:1353–5
Youngblood, M., Williams, P. D., Eyles, H.et al. (1994). A comparison of two methods of assessing cancer therapy-related symptoms.Cancer Nursing 17:37–44
Williams, P. D., Ducey, K. A., Sears, A. M.et al. (2001). Treatment type and symptom severity among oncology patients by self-report.International Journal of Nursing Studies 38:359–67
Munro, A. J., Potter, S. (1996). A quantitative approach to the distress caused by symptoms in patients treated with radical radiotherapy.British Journal of Cancer 74:640–7
Johnson, D. J., Casey, L., Noriega, B. (1994). A pilot study of patient quality of life during radiation therapy treatment.Quality of Life Research 3:267–72
Trotti, A., Johnson, D. J., Gwede, C.et al. (1998). Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI).International Journal of Radiation Oncology, Biology, and Physics 42:257–61
Brown, V., Sitzia, J., Richardson, A.et al. (2001). The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy.International Journal of Nursing Studies 38(5):497–510
Kurihara, M., Shimizu, H., Tsuboi, K.et al. (1999). Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapyPsycho-Oncology 8(4):355–63
Sitzia, J., Dikken, C., Hughes, J. (1997). Psychometric evaluation of a questionnaire to document side-effects of chemotherapy.Journal of Advanced Nursing 25(5):999–1007
Fallowfield, L. J., Leaity, S. K., Howell, A.et al. (1999). Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.Breast Cancer Research and Treatment 55(2):189–99
Aaronson, N., Ahmedzai, S., Bergman, B.et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.Journal of the National Cancer Institute 85:365–76